Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Association between clinicopathological features and pCR in FEC-Taxotere treated group (N = 118)

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

  Total pCR (N = 25) No pCR (N = 93) P value
N = 118 n %a n %a
Tumor size 
T0-T1 5 1 20.0 4 80.0  
T2 60 16 26.7 44 73.3  
T3 24 3 12.5 21 87.5  
T4 27 4 14.8 23 85.2 NS
NA 2 1   1   
Histopronostic grade
SBRI–SBRII 61 9 14.8 52 85.2  
SBRIII 43 16 37.2 27 62.8 0.009*
NA 14 0   14   
Nodal status
Positive 63 12 19.1 51 80.9  
Negative 53 12 22.6 41 77.4 NS
NA 2 1   1   
KI67
Positive 42 12 28.6 30 71.4  
Negative 6 0 0.0 6 100.0 NS
NA 70 13   57   
Hormone receptor status
RH
  Positiveb 77 12 15.6 65 84.4  
  Negativec 39 13 33.3 26 66.7 0.003*
  NA 2 0   2   
RE
  Positive 74 10 13.5 64 86.5  
  Negative 42 15 35.7 27 64.3 0.005*
  NA 2 0   2   
RP
  Positive 57 10 17.5 47 82.5  
  Negative 58 15 25.9 43 74.1 NS*
  NA 3 0   3   
Triple negative
  Yes 32 13 40.6 19 59.4  
  No 75 12 16.0 63 84.0 0.006*
  NA 11 0   11   
  1. NA not applicable, pCR pathological complete response.
  2. * Khi-2 test.
  3.  Fisher exact test.
  4.  Wilcoxon Mann–Whitney test.
  5. aPercentages of evaluable patients.
  6. bEstrogen receptor or progesterone receptor positive.
  7. cEstrogen receptor and progesterone receptor negative.